Lipitor patients warned of liver dysfunction

Published: 2006-07-07 06:58:00

Updated: 2006-07-07 06:58:00

The Korea Food and Drug Administration (KFDA) announced on July 4 improved labeling for Pfizer Korea's Lipitor tablets (atorvastatin calcium), which have been linked to reports of adverse reactions, such as liver dysfunction, jaundice, and hepatitis.

The KFDA said it is recommended that liver ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK